1. Home
  2. BACQ vs OLMA Comparison

BACQ vs OLMA Comparison

Compare BACQ & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BACQ
  • OLMA
  • Stock Information
  • Founded
  • BACQ 2024
  • OLMA 2006
  • Country
  • BACQ United States
  • OLMA United States
  • Employees
  • BACQ N/A
  • OLMA N/A
  • Industry
  • BACQ
  • OLMA Biotechnology: Pharmaceutical Preparations
  • Sector
  • BACQ
  • OLMA Health Care
  • Exchange
  • BACQ NYSE
  • OLMA Nasdaq
  • Market Cap
  • BACQ 333.2M
  • OLMA 289.0M
  • IPO Year
  • BACQ 2024
  • OLMA 2020
  • Fundamental
  • Price
  • BACQ $10.15
  • OLMA $4.60
  • Analyst Decision
  • BACQ
  • OLMA Strong Buy
  • Analyst Count
  • BACQ 0
  • OLMA 3
  • Target Price
  • BACQ N/A
  • OLMA $27.67
  • AVG Volume (30 Days)
  • BACQ 271.4K
  • OLMA 848.8K
  • Earning Date
  • BACQ 01-01-0001
  • OLMA 05-16-2025
  • Dividend Yield
  • BACQ N/A
  • OLMA N/A
  • EPS Growth
  • BACQ N/A
  • OLMA N/A
  • EPS
  • BACQ N/A
  • OLMA N/A
  • Revenue
  • BACQ N/A
  • OLMA N/A
  • Revenue This Year
  • BACQ N/A
  • OLMA N/A
  • Revenue Next Year
  • BACQ N/A
  • OLMA N/A
  • P/E Ratio
  • BACQ $112.74
  • OLMA N/A
  • Revenue Growth
  • BACQ N/A
  • OLMA N/A
  • 52 Week Low
  • BACQ $9.80
  • OLMA $2.86
  • 52 Week High
  • BACQ $10.14
  • OLMA $16.62
  • Technical
  • Relative Strength Index (RSI)
  • BACQ N/A
  • OLMA 49.07
  • Support Level
  • BACQ N/A
  • OLMA $4.35
  • Resistance Level
  • BACQ N/A
  • OLMA $5.74
  • Average True Range (ATR)
  • BACQ 0.00
  • OLMA 0.39
  • MACD
  • BACQ 0.00
  • OLMA -0.05
  • Stochastic Oscillator
  • BACQ 0.00
  • OLMA 17.99

About BACQ BLEICHROEDER ACQUISITION CORP. I

Bleichroeder Acquisition Corp I is a blank check company.

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: